Omega Diagnostics receives deferred £4m from CD4 sale

By Josh White

Date: Friday 25 Nov 2022

(Sharecast News) - Omega Diagnostics confirmed the receipt of deferred consideration from the sale of the CD4 business on Friday.
The AIM-traded medical diagnostics company said it had now received the £4m of deferred consideration.

"Accordingly, as of close-of-business on 24 November, Omega held cash balances of £6.5m," the board said in its short statement.

At 1116 GMT, shares in Omega Diagnostics Group were up 10.83% at 3.99p.

Reporting by Josh White for Sharecast.com.

« Go back to news channel

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE